A trial looking at quality of life in the treatment of patients with malignant pleural effusion

Submission date	Recruitment status No longer recruiting	Prospectively registered		
30/09/2015		[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
30/09/2015	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
24/11/2023	Cancer			

Plain English summary of protocol

http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-2-ways-to-treat-a-build-up-of-fluid-around-the-lung-optimum#undefined

Contact information

Type(s)

Scientific

Contact name

Dr Parthipan Sivakumar

ORCID ID

https://orcid.org/0000-0003-3740-2612

Contact details

St Thomas's Hospital 249 Westminster Bridge Road London United Kingdom SE1 7EH

Type(s)

Scientific

Contact name

Dr Liju Ahmed

ORCID ID

https://orcid.org/0000-0001-7722-8829

Contact details

St Thomas' Hospital Westminster Bridge Road London United Kingdom SE1 7EH +44 (0)20 7188 7188 liju.ahmed@gstt.nhs.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 19615

Study information

Scientific Title

Randomised controlled trial comparing outpatient management of malignant pleural effusion via an indwelling pleural catheter and talc pleurodesis versus standard inpatient management in improving health related quality of life

Acronym

OPTIMUM

Study objectives

The aim of the study is to investigate whether a better health related quality of life can be achieved with an indwelling pleural catheter and talc pleurodesis in managing malignant pleural effusion.

Ethics approval required

Old ethics approval format

Ethics approval(s)

First Medical Research Ethics Committee, 22/06/2015, ref: 15/LO/1018

Study design

Single-centre randomized parallel trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Cancer; Subtopic: Lung Cancer; Disease: Lung (non-small cell)

Interventions

Participants are randomly allocated into two groups.

Standard care arm: Participants undergo ultrasound guided 12F seldinger chest drain insertion and care as per the British Thoracic Society Guidelines. They will remain as an inpatient following chest drain insertion for drainage and instillation of talc pleurodesis. They will then undergo follow up at Day 7, 14, 30, 60, 90 with ultrasound, chest X-ray and quality of life and symptom questionnaires

Pleural catheter arm: Participants undergo ultrasound guided insertion of an indwelling pleural catheter. They will then be discharged and brought for follow up to assess for trapped lung. In the absence of trapped lung, patients will undergo talc pleurodesis on Day 4 with a view to drain removal on day 14. Patients will have follow up on day 30,60 and 90.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Health-related quality of life, measured using the EORTC QLQ-C30 questionnaire at baseline, 7, 14 and 30 days

Key secondary outcome(s))

- 1. Health-related quality of life, measured using the EORTC QLQ-C30 questionnaire at 60 and 90 days
- 2. Pleurodesis failure rate, measured using chest X-rays at baseline, 1, between 2-5, 7, 14, 30, 60 and 90 days
- 3. Improvement in symptoms of pain and breathlessness, measured using the visual analogue scale (VAS) and MRC dyspnea score at baseline, 7, 14, 30, 60 and 90 days
- 4. Complication rate

Completion date

27/01/2020

Eligibility

Key inclusion criteria

- 1. Age 18 years or over
- 2. Diagnosis of malignant pleural effusion
- 3. WHO performance status 2 or less unless performance status is impaired by presence of effusion and likely to significantly improve with drainage
- 4. Expected survival greater than 3 months

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

142

Key exclusion criteria

- 1. Aged less than 18 years old
- 2. Pregnant or lactating
- 3. Known allergy to Talc or Lignocaine
- 4. Lack of symptomatic relief from effusion drainage
- 5. At least twice weekly drainage cannot be undertaken
- 6. Lymphoma or small cell carcinoma except*:
- 6.1. Failure of chemotherapy
- 6.2. Deemed for palliative management
- 7. Non malignant effusions
- 8. Loculated pleural effusion
- 9. Unable to provide written informed consent to trial participation

*Lymphoma and small cell carcinoma are particularly sensitive to treatment with chemotherapeutic agents. If patients have undergone chemotherapy with no treatment response or deemed not for chemotherapy and for palliative management then they will be suitable for inclusion in the study. Liason with the patient's oncologist or MDT discussion will be required to ascertain this.

Date of first enrolment

29/07/2015

Date of final enrolment

27/10/2016

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
St Thomas's Hospital
249 Westminster Bridge Road
London
United Kingdom
SE1 7EH

Sponsor information

Organisation

Guy's & St Thomas' NHS Foundation Trust

ROR

https://ror.org/00j161312

Funder(s)

Funder type

Industry

Funder Name

CareFusion Corporation

Results and Publications

Individual participant data (IPD) sharing plan

The IPD from this trial will not be made available as the investigators do not have approval from their regional ethics committee to make this information available.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		23/11/2023	24/11/2023	Yes	No
Protocol article	protocol	18/10/2016		Yes	No
HRA research summary			28/06/2023		No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes